Helix BioMedix Inc. (OTCMKTS:HXBM – Get Free Report) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totaling 60 shares, a growth of ∞ from the May 31st total of 0 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 6 shares, the days-to-cover ratio is currently 10.0 days.
Helix BioMedix Price Performance
OTCMKTS:HXBM remained flat at $1.79 during mid-day trading on Thursday. Helix BioMedix has a 1 year low of $1.00 and a 1 year high of $6.45. The stock has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.78.
About Helix BioMedix
Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.
Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.
Featured Articles
- Five stocks we like better than Helix BioMedix
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Helix BioMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioMedix and related companies with MarketBeat.com's FREE daily email newsletter.
